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Proactive prophylaxis with azithromycin
and hydroxychloroquine in hospitalized
patients with COVID-19 (ProPAC-COVID): a
statistical analysis plan
Pradeesh Sivapalan1* , Charlotte Suppli Ulrik2, Therese Sophie Lappere3, Josefin Viktoria Eklöf1,
Saher Burhan Shaker1, Uffe Christian Steinholtz Bødtger4, Andrea Browatzki5, Christian Niels Meyer6,
Ulla Møller Weinreich7, Christian B. Laursen8, Tor Biering-Sørensen1, Filip Krag Knop1, Jens D. Lundgren9 and
Jens-Ulrik Stæhr Jensen1
Abstract
Background: There is an urgent need for treatments that can shorten hospitalization and lower the risk of
secondary infection and death in patients with corona disease. The ProPac-COVID trial evaluates whether
combination therapy with macrolide azithromycin and hydroxychloroquine via anti-inflammation/immune
modulation, antiviral efficacy, and pre-emptive treatment of supra-infections can shorten hospitalization duration
and reduce the risk of non-invasive ventilation, treatment in the intensive care unit, and death in patients with
acute hospital admission and a positive test for 2019-nCoV and symptoms of COVID-19 disease.
Methods: The ProPAC-COVID is a multi-center, randomized, placebo-controlled, double-blinded clinical trial. The
primary outcome is number of days spent alive and out of hospital within 14 days from randomization.
Randomization will be in blocks of unknown size, and the final allocation will be stratified for age, site of
recruitment, and whether the patient has any chronic lung diseases. Data is analyzed using intention-to-treat (ITT)
principles, and main analyses will also be subject to modified ITT analysis and per protocol analysis.
Discussion: This paper describes the detailed statistical analysis plan for the evaluation of primary and secondary
endpoints of the ProPAC-COVID study. Enrolment of patients to the ProPAC-COVID study is still ongoing. The
purpose of this paper is to provide primary publication of study results to prevent selective reporting of outcomes,
data-driven analysis, and to increase transparency.
Trial registration: ClinicalTrials.gov NCT04322396. Registered on 26 March 2020.
Keywords: Detailed statistical analysis plan, Randomized controlled trial, Infectious diseases, Safety,
Hydroxychloroquine, Azithromycin, Intervention
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Background
In the ongoing coronavirus disease 2019 (COVID-19)
pandemic that arose in Wuhan, China, there is still
sparse knowledge of the course, risk of complications,
and how hospitalized patients are best treated to ensure
best possible survival and shortest duration of
hospitalization. Presently, symptomatic and organ sup-
portive therapy, including assisted ventilation in acute
hypoxic respiratory failure, is recommended [1]. A high
incidence of bacterial super-infections in patients with
COVID-19 has been reported, and patients with more
severe COVID-19 seem to have a high risk of death due
to septic shock [2]. The length of hospitalization is ob-
served to be relatively long, 10–15 days [3], which in it-
self is a problem as hospitals can quickly reach the
maximum capacity for hospitalization and the propor-
tion of patients who become critically ill have, on the
observations reported so far, had a mortality rate of >
60% [4], and overall mortality for admitted patients in
China with COVID-19 infection is apparently unusually
high for viral respiratory tract infections, up to 25% [5].
Thus, there is an urgent need for treatments that can
improve patients’ outcomes in COVID-19 including
lower risk of secondary infection, death and shorter dur-
ation of hospital admission. The study will clarify
whether drug treatment with azithromycin in combin-
ation with hydroxychloroquine for 15 days from
hospitalization with diagnosed COVID-19 infection in
hospitalized patients may reduce the length of
hospitalization, the risk of hospitalization in the inten-
sive care unit (ICU), treatment with non-invasive venti-
lation (NIV), and death. The study will also clarify
whether this treatment can reduce the need for oxygen
supplementation (time for breathing on its own without
oxygen supplementation) or for regular long-term oxy-
gen therapy oxygen supplementation (“home oxygen”).
Research hypothesis
In patients with acute hospital admission, a positive test
for SARS-CoV-2 and symptomatic COVID-19 and treat-
ment with virus-modifying drug hydroxychloroquine as
well as virus-immunomodulatory and antibacterial drug
azithromycin can lead to shorter hospitalization and
fewer admissions to the ICU.
Study objectives
The objective of this randomized, placebo-controlled,
double-blinded multi-center trial is to investigate
whether 15-day treatment with azithromycin and hydro-
xychloroquine added to standard of care can shorten
hospitalization and reduce the risk of non-invasive venti-
lation, admittance to ICU, and death.
Study methods
Trial design
The patients are enrolled in the trial only after obtaining
informed consent. The trial is conducted at eight centers
in Denmark:
1. Section of Respiratory Medicine, Department of
Medicine, Herlev-Gentofte Hospital, University of
Copenhagen, Herlev and Hellerup, Denmark; princi-
pal investigator (PI): Jens-Ulrik Jensen, MD PhD
2. Department of Respiratory Medicine, Hvidovre
Hospital, University of Copenhagen, Hvidovre,
Denmark; PI: Charlotte Suppli Ulrik Professor, MD
DMSc.
3. Department of Pulmonary and Infectious Diseases,
Hillerød Hospital, University of Copenhagen,
Hillerød, Denmark; PI: Andrea Browatzki, MD
4. Department of Respiratory Medicine, Bispebjerg
Hospital, University of Copenhagen, Copenhagen,
Denmark; PI: Therese Lapperre, MD PhD
5. Department of Respiratory Medicine, Zealand
Hospital, Næstved Hospital, University of
Copenhagen, Næstved, Denmark; PI: Uffe Bødtger,
MD PhD
6. Department of Respiratory Medicine, Odense
University Hospital, University of Southern
Denmark, Odense, Denmark; PI: Christian B.
Laursen, MD PhD
7. Respiratory Medicine, Aarhus and Aalborg
University; PI: Ulla Weinreich, MD PhD
8. Department of Respiratory Medicine, Zeeland
University Hospital, Roskilde, PI: Christian Niels
Meyer, MD PhD
Patients will be randomized to one of two treatment arms:
i) Intervention group: Days 1–3: azithromycin 500
mg × 1 od plus hydroxychloroquine 200 mg × 2 od;
days 4–15: azithromycin 250 mg × 1 od plus
hydroxychloroquine 200 mg × 2 od
ii) Control group: The control group will receive
placebo for both types of intervention medications.
If the investigational therapy (or part of) becomes
standard treatment during the study, this may also
be offered to the control group
The analyses described in this document will be per-
formed by coordinating investigator Pradeesh Sivapalan,
MD PhD (Section of Respiratory Medicine, Department
of Medicine, Herlev-Gentofte Hospital, University of
Copenhagen, Herlev and Gentofte, Denmark) in cooper-
ation with the sponsor and principal investigator Jens
Ulrik Jensen, once the data have been entered, cleaned,
and released for use.
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This document provides a detailed description of the
statistical analyses that will be performed for the evalu-
ation of the primary and secondary endpoints of proto-
colized for the ProPAC-COVID study [6]. The analyses
described in this document are compatible with the rec-
ommendations of the CONSORT 2010 statement [7]
(Fig. 1). The International Conference on Harmonisation
(ICH) of Good Clinical Practice (GCP) [1] and leading
experts recommend that randomized clinical trials
should be analyzed according to predefined outcomes
and a predefined statistical analysis plan [2]. To prevent
selective reporting of outcomes and data-driven analysis
and to increase transparency, this paper describing the
detailed statistical analysis plan for the ProPAC-COVID
trial will be published while enrolment of patients and
collection of data is still ongoing and before the database
is accessed for trial results.
Statistical principles
Randomization
Randomization will be in blocks of unknown size and
the final allocation will be stratified for age (> 70 vs. ≤
70 years), site of recruitment, and whether the patient
has any of the following chronic lung diseases (yes vs.
no): chronic obstructive pulmonary disease, asthma,
bronchiectasis, and interstitial lung disease.
Analysis population
Data will be analyzed using intention-to-treat (ITT) prin-
ciples and main analyses will also be subject to modified
ITT analysis (started but not completed the study) and
per protocol analysis (completed all interventions). When
applying the ITT principle, all randomized patients will be
analyzed in the groups to which they were originally allo-
cated, regardless of whether they received the intended
treatment or whether a protocol violation or protocol
Fig. 1 CONSORT transparent reporting of trials
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deviation occurred. Patients who withdraw consent for the
use of their data will not be included in any analysis; only
the study group originally randomized to and withdrawal
of consent will be reported. A secondary analysis of the
primary efficacy outcome will use a per protocol (PP)
population. A CONSORT diagram of participants will be
presented in the study.
Sample size
The power to avoid a type II error is 80% (1-β) at a two-
sided 5% significance level, using a t test for the primary
outcome, and a group-sequential design allowing for one
interim analysis at half target recruitment. This led to a
sample size of 226 subjects. All confidence intervals
(CIs) reported will be 95% CIs. Full details of the sample
size calculation are described in the protocol article.
Analysis software
All analyses will be performed using SAS software ver-
sion 9.4.
Statistical interim analysis and stopping guidance
Planned analyses of safety and efficacy data (interim ana-
lysis) will be evaluated when 113 patients have completed
the study (completed 1-month follow-up). These assess-
ments will be made by an independent Data and Safety
Monitoring Board (DSMB). The interim analysis will focus
on reporting the following: selected baseline data (those
readily available from the baseline data list below), primary
outcome (in an O’ Brien-Fleming Plot), and all-cause mor-
tality at 30 days (chi-square or Fisher’s exact test, which-
ever appropriate). To adjust the type 1 error rate for
multiplicity, we will use the O’Brien-Fleming method in a
group-sequential design, resulting in an alpha level for the
interim analysis at 0.0054 and for the final analysis at
0.0492. The DSMB will review the protocol and monitor-
ing guideline, evaluate the attempts to recruit participants
and participants’ risk, and, on the basis of interim analyses,
make recommendations to investigators as to whether to
continue the study. In addition, the DSMB may at any
time require an extraordinary interim analysis.
Trial population
Descriptive analyses—baseline characteristics at study
enrolment (defined as day 1)
The following baseline characteristics of the study popu-
lation will be summarized separately within each ran-
domized group:
 Age, median (interquartile ranges (IQR)), years
 Male sex, n (%)
 Ethnicity (Caucasian, African (incl. African-
American), Asian, Inuit, unknown/other)
 Body mass index (kg/m2, median, IQR)
 Current smoker, n (%)
 Ex-smoker, n (%)
 Non-smoker, n (%)
 Pack-years history (median, IQR, years)
 Use of oxygen therapy, n (%)
 Use of continuous positive airway pressure, n (%)
 Use of non-invasive mechanical ventilation (NIV), n (%)
 Infiltrates on chest X-ray, n (%)
 Oxygen consumption: L/min (median, IQR)
 Oxygen consumption: fraction of inspired oxygen
(FiO2 (median, IQR))
Clinical findings (daily measurements)
 Systolic blood pressure (mm Hg)
 Diastolic blood pressure (mm Hg)
 Heart rate, beats/min
 Oxygen saturation with high flow nasal cannula,
median, IQR
 Respiratory rate, breaths/min
 Temperature (°C)
Biochemistry findings (daily measurements)
 Leukocyte count, × 109 cells/L
 Blood eosinophil count, × 109 cells/L
 Lymphocyte count, × 109 cells/L
 CRP (mg/L)
 Fibrin D-dimer (ng/mL)
 Ferritin (μg/L)
 Lactate dehydrogenase (U/L)
Arterial blood gas (mean ± standard deviation), day 1
and day 4
 PCO2, mmHg
 PO2, mmHg
 HCO3−
 pH
Other lab findings
 QTc (F) (via electronic measurement on
electrocardiogram (ECG) at baseline)
Comorbid conditions, n (%)
 Asthma
 COPD
 Bronchiectasis
 Interstitial lung disease
 Allergy
 Diabetes mellitus
 Previous myocardial infarction
Sivapalan et al. Trials          (2020) 21:867 Page 4 of 9
 Heart failure
 Atrial fibrillation
 Chronic renal failure
 Essential hypertension
 Osteoporosis
 Peripheral vascular disease
 Cerebrovascular disease
 Hematological diseases
 Depression
 Past or present lung cancer
 Previous or present non-lung cancer
 Previous thrombo-embolic disease (deep vein
thrombosis/pulmonary embolism)
 Liver failure
 Rheumatic diseases
Follow-up data and handling of missing data
The percentage of patients followed for each outcome
data parameter will be reported for all predefined out-
comes (primary and all secondary). Exploratory outcome
analyses will be planned by the study group on suggestion
form the reviewers/editors etc. Percentage with followed/
missing data will also be reported for these outcomes.
Adherence data
N + % patients in both arms who:
– Started azithromycin
– Started hydroxychloroquine
– Completed azithromycin (all days)
– Completed hydroxychloroquine (all days)
– Completed both drugs (all days)
Medication during hospitalization
 Type of antibiotics (non-study drugs)
 Ciprofloxacin, piperacillin/tazobactam,
ceftazidime, meropenem, colistin, gentamycin,
amoxicillin, amoxicillin/clavulanic acid,
roxithromycin, dicloxacillin, penicillin,
azithromycin, or others
 Days with antibiotics—any (median days on any type)
 Days with corticosteroids (median days)
For continuous variables, means and standard deviations
will be presented, when normally distributed, otherwise as
medians and IQR. For categorical variables, the number
and percentage of participants within each category will
be presented. For each variable, the percent of missing
values will be reported. For categorical values, chi-square
and Fisher’s exact test will be used. For time-to-event vari-
ables, Cox regression and log-rank test will be used, and
for the latter, a corresponding Kaplan-Meier plot will be
presented.
Data analysis
Primary objective and outcome
The primary outcome is a continuous outcome: “days
alive and out of hospital within 14 days (DAOH14) after
recruitment.” The outcomes are defined as number of
days spent alive and out of hospital within 14 days from
randomization. This is sensitive outcome used in previ-
ous publications [8, 9]. Among other advantages, lead-
time bias due to death was avoided using this endpoint
measure (i.e., patients who died early would not be
counted as a short length of stay). Data for the primary
outcome will be analyzed using a general linear model
adjusted for the stratification covariates (age, site, and
chronic lung disease) and estimated means and differ-
ence in means with 95% CI will be presented. Addition-
ally, for sensitivity analysis median with IQR with
corresponding non-parametric test, e.g., Mann-Whitney
U test will be presented. In the case of missing covariate
data, multiple imputations will be used. The estimation
from the study group is that DAOH14 will be a number
above or equal to 4. If DAOH14 is < 4, DAOH at 21 days
will be presented instead. Apart from the main analysis,
the primary outcome analysis will be performed as an
adjusted analysis using general linear models while
adjusting for the following variables: age (per year in-
crease), sex (M/F), COPD GOLD C/D (yes vs. no), heart
failure NYHA III-IV (yes vs. no), and current smoker
(yes vs. no).
Secondary objective and outcomes
1. Categorization of hospitalization status [time frame:
14 days]
The patient will be categorized into one of the following
8 categories depending on status of their hospitalization.
Only one category can be “yes”:
a. Dead (yes/no)
b. Hospitalized and receiving mechanical ventilation
or extra corporal membrane oxygenation (yes/no)
c. Hospitalized and receiving NIV or using high-flow
oxygen device (yes/no)
d. Hospitalized and given oxygen supplements
different from (b) and (c) (yes/no)
e. Hospitalized and without oxygen treatment, but
receiving other treatment (both related to COVID-
19 or other) (yes/no)
f. Hospitalized for observation (yes/no)
g. Discharged from hospital with restriction of activity
level (yes/no)
h. Discharged from hospital without any restrictions
of activity level (yes/no)
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For this analysis, the patient will be assigned a number
between 1 and 8. Frequencies for the categories will be
presented. A proportional odds logistic regression model
will be applied. The key parameter of interest is the
“common odds ratio,” which quantifies the shift in the
severity distribution resulting from treatment. For an ef-
ficacious treatment, an odds ratio greater than 1 quanti-
fies an improvement in disease severity; a value of 2
indicates a bigger improvement than a value of 1.25. If
the preconditions for the proportional odds model are
not considered fulfilled, we will present the frequencies
and calculate p values for shifts in levels by a Wilcoxon
rank-sum test.
2. Admitted to ICU, if admitted to ICU then length of
stay [time frame: 14 days]
Number of patients admitted to intensive care will be
compared using chi-square test. Length of stay in ICU
will be analyzed using a t test. Days not alive within the
time frame will be added to days at ICU. If days not alive
are equal in the two treatment groups, we will further
present days at ICU excluding days not alive.
3. Have required NIV during hospitalization [time
frame: 14 days]
Use of NIV will be compared by a chi-square test.
4. Mortality [time frame: 30 days]
Differences in mortality will be calculated using Cox
proportional hazards adjusting for the following vari-
ables: age (per year increase), sex (M/F), COPD GOLD
C/D (yes vs. no), heart failure NYHA III-IV (yes vs. no),
and active smoker (yes vs. no). Treatment effects will be
presented as hazard ratios (HR) and 95% CIs. Further-
more, Kaplan-Meier plot will be presented in combin-
ation with the log-rank test. Patients will be censored in
the case of lost to follow-up.
5. Length of hospitalization [time frame: 14 days]
Length of hospitalization between groups will be com-
pared using a t test.
6. Days alive and discharged from hospital [time
frame: 30 days]
This is equal to the primary endpoint but with a lon-
ger time frame and will be analyzed similarly.
7. Mortality [time frame: 90 days]—to be reported in a
secondary publication
Differences in mortality will be calculated using Cox
proportional hazards adjusting for the following vari-
ables: age (per year increase), sex (M/F), COPD GOLD
C/D (yes vs. no), heart failure NYHA III-IV (yes vs. no),
and active smoker (yes vs. no). Treatment effects will be
presented as hazard ratios (HRs) and 95% CIs. Further-
more, Kaplan-Meier plot will be presented in combin-
ation with the log-rank test. Patients will be censored in
the case of lost to follow-up. However, this is not ex-
pected, since follow-up for these values is 100.0% in the
Danish health registry.
8. Mortality [time frame: 365 days]—to be reported in
a secondary publication
Differences in mortality will be estimated using both
unadjusted and adjusted analyses. For the adjusted
analysis, a Cox proportional hazards model will be
used and adjustment for the following variables will
be done: age (per year increase), sex (M/F), COPD
GOLD C/D (yes vs. no), heart failure NYHA III-IV
(yes vs. no), and active smoker (yes vs. no). Treat-
ment effects will be presented as HRs and 95% CIs.
Furthermore, Kaplan-Meier plot will be presented in
combination with the log-rank test. Patients will be
censored in the case of lost to follow-up.
9. Time to readmission (all causes) [time frame: 30 days]
10. Differences in readmission will be calculated using
Cox proportional hazards adjusting for the following
variables: age (per year increase), sex (M/F), COPD
GOLD C/D (yes vs. no), heart failure NYHA III-IV
(yes vs. no), and active smoker (yes vs. no). Treat-
ment effects will be presented as HRs and 95% CIs.
Furthermore, Kaplan-Meier plot will be presented in
combination with the log-rank test. Patients will be
censored in the case of lost to follow-up. Number of
days requiring NIV [time frame: 14 days]
11. Number of days on NIV will be compared using a t
test. If patients die within 14 days, days of death will
be counted as days in NIV. Change in patient’s
oxygen partial pressure [time frame: 4 days]
Delta PaO2 measured in arterial blood gas analysis.
Changes will be calculated by an analysis of covariance
(ANCOVA) method adjusting for baseline values.
12. Change in patient’s PCO2 partial pressure [time
frame: 4 days]
Delta PaCO2 measured in arterial blood gas analysis.
Changes will be calculated by an ANCOVA method
adjusting for baseline values.
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13. Level of pH in blood [time frame: 4 days]
pH measured in arterial blood gas analysis.
Levels in pH will be compared using a t test.
14. Time to no oxygen supplement (or regular oxygen
supplement “long-term oxygen therapy”) [time
frame: 14 days]
Time to no oxygen supplement will be presented by
the Kaplan-Meier method and differences calculated by
log-rank test.
For all analyses using parametric statistics (t test,
ANCOVA), the distribution will be inspected. Biochem-
ical markers will be transformed if necessary whereas
length of stays will not be transformed. If parametric sta-
tistics is considered inappropriate, a non-parametric
Table 1 SPIRIT figure: overview of examinations that each participant will undergo
STUDY PERIOD
Enrolment Allocation Post-allocation (days)
Timepoint -24 hours 1 2-3 4 5 to 
discharge
15
ENROLMENT:
Informed consent X
Eligibility screening X
Allocation X
INTERVENTION:
Group 0: Placebo treatment
Group 1: Azithromycin 
/hydroxychloroquine 
treatment
EXAMINATIONS:
Blood sample* X X X X
Pregnancy test (only fertile 
women) X
Arterial blood gas X X
ECG** X X*** X X
MRC score + GOLD**** X
Body mass index (BMI) X
Oxygen supplementation 
(L/min) (open) X X X X
FiO2 (%) (respirator) N/A X X X
Chest x-ray During hospital admission
*The blood samples include hemoglobin (Hb), leukocytes + differential count, thrombocytes, C-reactive protein (CRP), Na+, K+, albumin, creatinine, urea, amylase,
alkalic phosphatase, beta-2-microglubulin, fibrinogen, glucose, TSH, INR, bilirubin, D-dimer, APTT, calcium, triglycerides, ferritin, and lactate dehydrogenase (LDH).
These blood tests will also be recommended daily for COVID patients outside studies in the recommendation of the Danish lung medicine association
**When screening for the study, any ECG from within the last 3 days can be used
***A follow-up ECG can be recorded during any remaining days of the hospital admission
****Only in patients with COPD
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alternative will be used. For analyses with a dichotomous
outcome, Fisher’s exact test will be used if the chi-
square test is not considered appropriate.
Arrhythmias:
– ECG: QTc: n (%) patients in both arms who at any
time point after baseline had a QTc (F) > 500 ms.
We will do separate analysis for men and women.
– N (%) ventricular arrhythmias (apart from
ventricular extrasystoles and non-sustained ventricu-
lar tachycardia)
Subgroup analyses (all according to baseline values)
Scheduled to perform the following stratified analyses
for the primary outcome:
– Stratified analyzes in the presence of chronic lung
disease or not
– Stratified analyzes for QTc across the median
– Stratified analyzes for < 2 L/min nasal oxygen vs. ≥ 2
L nasal oxygen
– Stratified analyzes CRP < 50mg/L and CRP ≥ 50mg/L
– Stratified analyzes D-dimer > 0.8 mg/L or D-dimer
≥ 0.8 mg/L
– Stratified for remdesivir treatment (yes or no)
Figures and tables
The first figure will be a consolidated standards of report-
ing of randomized trials (CONSORT) flow chart. The sec-
ond figure will be a Kaplan-Meier plot to describe the rate
of death by treatment arms. The third figure will be a for-
est plot illustrating all the preplanned sub analyses. The
first table will be the baseline characteristics of the ITT
population (Table 1). The second table will include the
primary and secondary outcomes according to the two al-
location and pairwise comparisons.
Blinding of the statistician
The detailed analysis plan was written in strict concord-
ance with the trial protocol approved by the regulatory
authorities prior to recruitment initiation. The entire
statistical analysis plan was published at www.coptrin.dk
before the trial was finalized (before the database was
closed). All analyses will be done prior to breaking of
the randomization code (analysis comparisons between
“arm A” and “arm B” (random names). The coordinating
investigator (PS) and the study sponsor and principal in-
vestigator (JUJ) will conjointly perform all the data ana-
lyses according to this plan, except the interim analyses
which will be performed by Dr. Josefin Eklöf (who is not
an investigator of this trial) from Section of Respiratory
Medicine, Department of Medicine, Gentofte Hospital,
University of Copenhagen, Hellerup, Denmark. An
unblinding date will be chosen and published online at
www.coptrin.dk, and on this date, the allocation will be
unblinded. After unblinding of the allocation, further
analysis will not be done, except on request from re-
viewers/editors handling submitted papers.
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